Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues

World Journal of Gastroenterology

Volumn 18, Issue 48, 2012, Pages 7149-7157

  Song, Zhuo Lun ^a   Cui, Yu Jun ^b   Zheng, Wei Ping ^b   Teng, Da Hong ^b   Zheng, Hong ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Gene mutation; Hepatitis B virus; Liver transplantation; Multi drug resistance; Nucleos(t)ide analogues

Indexed keywords

ADEFOVIR; ALPHA1 INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; GENE MUTATION; HEPATITIS B; HUMAN; LIVER GRAFT; LOW DRUG DOSE; MONOTHERAPY; MULTIDRUG RESISTANCE; PHENOTYPE; REVIEW; VIRUS GENOME; VIRUS LOAD;

EID: 84878840396     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i48.7149     Document Type: Review

References (101)

1. Baumert TF, Thimme R, von Weizsäcker F. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13: 82-90
2. Murray JM, Purcell RH, Wieland SF. The half-life of hepatitis B virions. Hepatology 2006; 44: 1117-1121
3. Zoulim F, Buti M, Lok AS. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing? J Viral Hepat 2007; 14(Suppl 1): 29-36
4. Alazawi W, Foster GR. Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis 2008; 21: 508-515
5. Leemans WF, Janssen HL, Niesters HG, de Man RA. Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. J Viral Hepat 2008; 15: 108-114
6. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32: 866-867
7. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2: 147-151
8. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297
9. van Bömmel F, Zollner B, Moller B, Huppe D, Feucht HH, Wiedenmann B, Berg T. Is tenofovir effective in treatment of adefovir resistant hepatitis B virus (HBV) infections? Hepatology 2006; 44(Suppl 1): 567A
10. Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Kawamura Y, Hosaka T, Kobayashi M, Ikeda K, Kobayashi M, Watahiki S, Kumada H. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. J Clin Virol 2007; 39: 149-152
11. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis 2010; 14: 439-459
12. Dupouey J, Gerolami R, Solas C, Colson P. Hepatitis B virus variant with the a194t substitution within reverse transcriptase before and under adefovir and tenofovir therapy. Clin Res Hepatol Gastroenterol 2012; 36: e26-e28
13. Tacke F, Trautwein C. Hepatitis B goes globe: Telbivudine as a new treatment option. Hepatology 2008; 47: 1786-1787
14. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075
15. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391-398
16. Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008; 20: 773-777
17. Choe WH, Kwon SY, Kim BK, Ko SY, Yeon JE, Byun KS, Kim GH, Lee CH. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28: 814-820
18. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49: 1158-1165
19. Reijnders JG, la Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist 2009; 2: 13-26
20. Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. World J Gastroenterol 2009; 15: 753-755
21. Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10: 727-734
22. Delaney WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50: 2471-2477
23. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12: 341-353
24. Sayan M, Hulagu S, Karatayli SC. Multidrug-resistant hepatitis B virus strain in a chronic Turkish patient. Hepat Mon 2010; 10: 141-146
25. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207-210
26. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242
27. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662
28. Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101
29. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-290
30. Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010; 53: 449-454
31. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, Chung YH, Lee YS, Yoo W, Kim SO. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-1391
32. Lee JM, Park JY, Kim Do Y, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther 2010; 15: 235-241
33. Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, Yuen MF. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007; 12: 41-46
34. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313
35. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44: 703-712
36. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouée-Durantel S, Villeneuve JP, Trépo C, Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398
37. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trépo C, Zoulim F. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078-1088
38. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
39. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695
40. Rang A, Günther S, Will H. Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol 1999; 31: 791-799
41. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178
42. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283
43. Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J Viral Hepat 2011; 18: e475-e481
44. Choe WH, Hong SP, Kim BK, Ko SY, Jung YK, Kim JH, Yeon JE, Byun KS, Kim KH, Ji SI, Kim SO, Lee CH, Kwon SY. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir. Antivir Ther 2009; 14: 985-993
45. Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother 2012; 56: 2941-2947
46. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/ nucleotide analogues. Hepatology 2010; 51: 73-80
47. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325
48. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254
49. Petersen J, Ratziu V, Buti M, Janssen HL, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56: 520-526
50. Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011; 5: 278-287
51. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108
52. Ustundag Y, Topalak O. Think twice if you consider entecavir treatment in cases with lamivudine refractoriness. Hepatology 2010; 52: 397-398
53. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J, Yang JY, Xu D, Brett-Smith H, Kreter B, Colonno RJ, Neo BL. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. J Gastroenterol Hepatol 2008; 23 Suppl 5: A29
54. Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki F, Kumada H, Chayama K. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol 2007; 79: 1811-1817
55. Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. Efficacy of entecavir and adefovir combination therapy for patients with lamivudineand entecavirresistant chronic hepatitis B. Dig Dis Sci 2012; 57: 1358-1365
56. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, Wang H, Xin S, Zoulim F, Xu D. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir Ther 2010; 15: 1185-1190
57. Karatayli E, Karatayli SC, Cinar K, Gokahmetoglu S, Güven K, Idilman R, Yurdaydin C, Bozdayi AM. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J Clin Virol 2012; 53: 130-134
58. D'Avola D, Herrero JI. Prophylaxis and treatment of hepatitis B infection in the setting of liver transplantation. Rev Esp Enferm Dig 2011; 103: 142-149
59. Subramanian AK. Antimicrobial prophylaxis regimens following transplantation. Curr Opin Infect Dis 2011; 24: 344-349
60. Buchanan C, Tran TT. Current status of liver transplantation for hepatitis B virus. Clin Liver Dis 2011; 15: 753-764
61. Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, Lok AS. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007; 5: 1454-1461
62. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008; 15: 89-102
63. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700
64. Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15: 2489-2499
65. Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, Nishijima N, Takada Y, Uemoto S, Chiba T. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther 2011; 16: 479-487
66. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18: 97-115
67. Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY, Boillot O. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007; 7: 177-184
68. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final longterm results. Liver Transpl 2007; 13: 349-360
69. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130-2134
70. Limquiaco JL, Wong J, Wong VW, Wong GL, Tse CH, Chan HY, Kwan KY, Lai PB, Chan HL. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009; 81: 224-229
71. Wai CT, Prabhakaran K, Wee A, Lee YM, Dan YY, Sutedja DS, Mak K, Isaac J, Lee KH, Lee HL, Da Costa M, Lim SG. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplant Proc 2004; 36: 2313-2314
72. de Tejada Echanojáuregui A, Moreno Planas JM, Rubio González E, Portero Azorin F, López Monclús J, Revilla Negro J, de la Poza JL, Sánchez Turrión V, Barrios Peinado C, Cuervas-Mons Martínez V. Adefovir dipivoxil therapy in liver transplant recipients with lamivudineresistant hepatitis B virus. Transplant Proc 2005; 37: 1507-1508
73. Neff GW, O'brien CB, Nery J, Shire N, Montalbano M, Ruiz P, Nery C, Safdar K, De Medina M, Tzakis AG, Schiff ER, Madariaga J. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-1378
74. Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl 2008; 14 Suppl 2: S15-S22
75. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, Shen CH, Luo Y, Xin TY, Wang SY, Qiu de K. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327
76. Jiménez-Pérez M, Sáez-Gómez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-López JM. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010; 42: 3167-3168
77. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219
78. Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131: 1253-1261
79. Karlas T, Hartmann J, Weimann A, Maier M, Bartels M, Jonas S, Mössner J, Berg T, Tillmann HL, Wiegand J. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis 2011; 13: 299-302
80. Khudyakov Y. Coevolution and HBV drug resistance. Antivir Ther 2010; 15: 505-515
81. Cassino L, Laufer N, Salomon H, Campos R, Quarleri J. Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBV-HIV coinfected patients: a 3-yr prospective study. J Clin Virol 2009; 46: 354-359
82. Wang F, Wang H, Shen H, Meng C, Weng X, Zhang W. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin Ther 2009; 31: 360-366
83. Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo CG, Lok A, Khudyakov Y. Convergence and coevolution of hepatitis B virus drug resistance. Nat Commun 2012; 3: 789
84. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593.e1-2-1608.e1-2
85. Ko SY, Oh HB, Park CW, Lee HC, Lee JE. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect 2012; 18: E404-E411
86. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-1145
87. Metzker ML. Sequencing technologies the next generation. Nat Rev Genet 2010; 11: 31-46
88. Rodriguez-Frías F, Tabernero D, Quer J, Esteban JI, Ortega I, Domingo E, Cubero M, Camós S, Ferrer-Costa C, Sánchez A, Jardí R, Schaper M, Homs M, Garcia-Cehic D, Guardia J, Esteban R, Buti M. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One 2012; 7: e37874
89. Damerow H, Yuen L, Wiegand J, Walker C, Bock CT, Locarnini S, Tillmann HL. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010; 82: 1850-1858
90. Lo CM, Cheung CK, Lau GK, Yuen MF, Liu CL, Chan SC, Fan ST, Wong J. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 2005; 5: 1893-1900
91. Yildiz O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yildirmak T, Kantürk A, Tütüncü E. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17: 4987-4992
92. Wong VW, Sung JJ. Diagnosis and personalized management of hepatitis B including significance of genotypes. Curr Opin Infect Dis 2012; 25: 570-577
93. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011; 31(Suppl 1): 111-116
94. Tujios SR, Lee WM. New advances in chronic hepatitis B. Curr Opin Gastroenterol 2012; 28: 193-197
95. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184
96. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34: 1145-1158
97. Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009; 9: 256-264
98. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897
99. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012; 56(Suppl 1): S112-S122
100. An P, Bian L, Yin B, Lv D, Cao YX, Wu X. Risk factors of gene-resistant mutations in different nucleosides. Hepatogastroenterology 2012; 59: 228-230
101. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185